FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024508357> ?p ?o ?g. }

• W2024508357 abstract "You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Interstitial Cystitis1 Apr 2013872 CLINICAL RESPONSE TO INTRA-TRIGONAL ONABOTULINUM TOXIN A INJECTIONS IS NOT RELATED TO THE PRESENCE OF ULCERS IN BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS PATIENTS Rui Pinto, Tiago Lopes, João Silva, Carlos Silva, Paulo DInis, and Francisco Cruz Rui PintoRui Pinto Porto, Portugal More articles by this author , Tiago LopesTiago Lopes Porto, Portugal More articles by this author , João SilvaJoão Silva Porto, Portugal More articles by this author , Carlos SilvaCarlos Silva Porto, Portugal More articles by this author , Paulo DInisPaulo DInis Porto, Portugal More articles by this author , and Francisco CruzFrancisco Cruz Porto, Portugal More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.441AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Recently we showed that intra-trigonal Onabotulinum toxin A (OnaBotA) injection provides prolonged relief of bladder pain in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) patients. Since injections were not performed in the ulcerative area, we investigated if the toxin provided a different symptomatic outcome and duration of effect in the two phenotypes of BPS/IC, the ulcerative and the non-ulcerative form. METHODS 10 ulcerative (Ulc) and 14 non-ulcerative (NUlc) BPS/IC patients were evaluated at presentation and 1 month after intra-trigonal injection of 100U of OnaBotA. A 10-point Visual Analogue Scale (VAS) was used to quantify pain. Frequency and nocturia in a 3-day voiding chart, O'Leary-Sant Score (OSS), QoL and duration of the effect were evaluated. Urinary norepinephrine was accessed by ELISA. RESULTS Patients had a mean age of 40±12 y in the Ulc and 47±13 y in the NUlc group (non-significant, ns). The ESSIC classification was 2a (3), 2b (5), 2c (6) in the NUlc group and 3a (1), 3b (3) and 3c (6) in the Ulc form group. Patients with the Ulc phenotype had a longer duration of symptoms (28.8±11 vs 19.2±8 months, p=0.018). Mean values at baseline of pain, frequency, nocturia, OSS, QoL were identical on the two groups. Likewise, the urinary norepinephrine was identical (Table 1). The two groups responded equally to OnaBotA with a marked decrease in pain, frequency, nocturia, OSS, QoL and in urinary norepinephrine levels (Table). The duration of the effect, 9±2.8 in the Ulc and 10.5±2 months in the NUlc disease was similar. CONCLUSIONS The symptom relief brought by trigonal OnabotA suggests that pain is not directly related with the ulcers themselves. We could not find symptomatic differences between those two phenotypes, challenging the traditional view that Ulc BPS/IC patients have a more symptomatic form of the disease. Ulcerative BPS/IC N=10 Non-ulcerative BPS/IC N=14 p After OnabotA Ulcerative BPS/IC N=10 After OnabotA Non-ulcerative BPS/IC N=14 p VAS 6.3 ± 0.9 5.6 ± 0.5 ns 2.9 ± 1.4 2.4 ± 1 ns Frequency 11.2 ± 2.4 10.3 ± 1.9 ns 7.9 ± 1 7.9 ± 0.9 ns Nocturia 5.9 ± 1 4.9 ± 0.5 ns 2 ± 1 1.9 ± 0.7 ns O'Leary-Sant Symptoms Score 16.6 ± 1 15.9 ± 0.8 ns 10 ± 2.4 8.7 ± 1.3 ns O'Leary-Sant Problems Score 12.8 ± 1 12.5 ± 0.7 ns 6.9 ± 1.2 6.6 ± 0.7 ns QoL (IPSS) 5.8 ± 0.4 5.9 ± 0.3 ns 2 ± 1.2 1.7 ± 1 ns Norepinephrine (24h-urine) 104.4 ± 38 100 ± 50.3 ns 77.2 ± 28 72.8 ± 31 ns © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e360 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rui Pinto Porto, Portugal More articles by this author Tiago Lopes Porto, Portugal More articles by this author João Silva Porto, Portugal More articles by this author Carlos Silva Porto, Portugal More articles by this author Paulo DInis Porto, Portugal More articles by this author Francisco Cruz Porto, Portugal More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2024508357 created "2016-06-24" @default.
• W2024508357 creator A5007372313 @default.
• W2024508357 creator A5023888367 @default.
• W2024508357 creator A5038662879 @default.
• W2024508357 creator A5062616278 @default.
• W2024508357 creator A5075415353 @default.
• W2024508357 creator A5075462647 @default.
• W2024508357 date "2013-04-01" @default.
• W2024508357 modified "2023-10-17" @default.
• W2024508357 title "872 CLINICAL RESPONSE TO INTRA-TRIGONAL ONABOTULINUM TOXIN A INJECTIONS IS NOT RELATED TO THE PRESENCE OF ULCERS IN BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS PATIENTS" @default.
• W2024508357 doi "https://doi.org/10.1016/j.juro.2013.02.441" @default.
• W2024508357 hasPublicationYear "2013" @default.
• W2024508357 type Work @default.
• W2024508357 sameAs 2024508357 @default.
• W2024508357 citedByCount "2" @default.
• W2024508357 countsByYear W20245083572014 @default.
• W2024508357 countsByYear W20245083572016 @default.
• W2024508357 crossrefType "journal-article" @default.
• W2024508357 hasAuthorship W2024508357A5007372313 @default.
• W2024508357 hasAuthorship W2024508357A5023888367 @default.
• W2024508357 hasAuthorship W2024508357A5038662879 @default.
• W2024508357 hasAuthorship W2024508357A5062616278 @default.
• W2024508357 hasAuthorship W2024508357A5075415353 @default.
• W2024508357 hasAuthorship W2024508357A5075462647 @default.
• W2024508357 hasConcept C126322002 @default.
• W2024508357 hasConcept C126894567 @default.
• W2024508357 hasConcept C141071460 @default.
• W2024508357 hasConcept C14184104 @default.
• W2024508357 hasConcept C2777333188 @default.
• W2024508357 hasConcept C2778508898 @default.
• W2024508357 hasConcept C2909931192 @default.
• W2024508357 hasConcept C71924100 @default.
• W2024508357 hasConcept C77411442 @default.
• W2024508357 hasConceptScore W2024508357C126322002 @default.
• W2024508357 hasConceptScore W2024508357C126894567 @default.
• W2024508357 hasConceptScore W2024508357C141071460 @default.
• W2024508357 hasConceptScore W2024508357C14184104 @default.
• W2024508357 hasConceptScore W2024508357C2777333188 @default.
• W2024508357 hasConceptScore W2024508357C2778508898 @default.
• W2024508357 hasConceptScore W2024508357C2909931192 @default.
• W2024508357 hasConceptScore W2024508357C71924100 @default.
• W2024508357 hasConceptScore W2024508357C77411442 @default.
• W2024508357 hasIssue "4S" @default.
• W2024508357 hasLocation W20245083571 @default.
• W2024508357 hasOpenAccess W2024508357 @default.
• W2024508357 hasPrimaryLocation W20245083571 @default.
• W2024508357 hasRelatedWork W1556555673 @default.
• W2024508357 hasRelatedWork W2024508357 @default.
• W2024508357 hasRelatedWork W2035474551 @default.
• W2024508357 hasRelatedWork W2039941522 @default.
• W2024508357 hasRelatedWork W2064218429 @default.
• W2024508357 hasRelatedWork W2376670468 @default.
• W2024508357 hasRelatedWork W2625769102 @default.
• W2024508357 hasRelatedWork W3080980001 @default.
• W2024508357 hasRelatedWork W3142122330 @default.
• W2024508357 hasRelatedWork W3196774595 @default.
• W2024508357 hasVolume "189" @default.
• W2024508357 isParatext "false" @default.
• W2024508357 isRetracted "false" @default.
• W2024508357 magId "2024508357" @default.
• W2024508357 workType "article" @default.